US › Healthcare

Janux Therapeutics Inc (JANX)

US · Healthcare · Biotechnology

$15.96+4.18%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.7M
Net profit
$-24.4M
Profit YoY
-3.6%
EPS
$-0.39
EPS estimate
$-0.52
Net margin
-652.6%

EPS came in at -0.39 against a street estimate of -0.52 — a beat of 25.0%.

Key statistics

Market cap
$934.3M
Forward P/E
0.0
P/B
0.98
Book value
$15.47
EPS (TTM)
$-1.84
52-week high
$35.34
52-week low
$12.12
50-day MA
$14.89
200-day MA
$16.84
Beta
2.51

Analyst view

Analysts rate Janux Therapeutics Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $37.19.

Shareholding

Insiders
1.70%
Institutions
102.84%

Largest institutional holders

FundStake
RA Capital Management, LLC18.35%
BlackRock Inc8.91%
HHG PLC6.88%
Prosight Management, LP5.82%
Vanguard Group Inc4.77%
FMR Inc4.16%
State Street Corp4.04%
Vanguard Capital Management, LLC2.97%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Janux Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.